Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD LNA043 - ANGPTL3 Agonist Study Indication Phase Patients Primary Outcome Measures NCT03275064 (CLNA043X2202) Knee osteoarthritis Phase 2 133 Articular cartilage bi-layer collagen organisation evaluated with MRI and measured in milliseconds (ms) (Part A only) Number of patients with any adverse events, serious adverse events and death (Part A and Part B) Change in cartilage volume/thickness in the index region (Part B only) NCT04864392 ONWARDS (CLNA043A12202) Knee osteoarthritis Phase 2 550 Change from baseline in the cartilage thickness of the medial compartment of the knee as assessed by imaging Arms Intervention LNA043 40 mg Part B LNA043 20 mg Part B LNA043 20 mg Part A Placebo Part A Placebo Part B Patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B) LNA043 injection to the knee with dosing regimen A LNA043 injection to the knee with dosing regimen B LNA043 injection to the knee with dosing regimen C LNA043 injection to the knee with dosing regimen D Placebo injection to the knee Patients with Symptomatic knee osteoarthritis Target Patients Read-out Milesstone(s) 2022 Publication 81 Investor Relations | Q2 2021 Results TBD Primary 2024 TBD 1 NOVARTIS | Reimagining Medicine

View entire presentation